{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T10:59:08Z","timestamp":1793876348726,"version":"4.7.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,2,22]],"date-time":"2022-02-22T00:00:00Z","timestamp":1645488000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,22]],"date-time":"2022-02-22T00:00:00Z","timestamp":1645488000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Patients with large granular lymphocytic leukemia (LGLL) frequently present with neutropenia. When present, anemia is usually accompanied by neutropenia and\/or thrombocytopenia and isolated anemia is uncommon. We evaluated a cohort of 244 LGLL patients spanning 15 years and herein report the clinicopathologic features of 34 (14%) with isolated anemia. The patients with isolated anemia showed a significantly male predominance (<jats:italic>p<\/jats:italic>\u2009=\u20090.001), a lower level of hemoglobulin (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001) and higher MCV (<jats:italic>p<\/jats:italic>\u2009=\u20090.017) and were less likely to have rheumatoid arthritis (<jats:italic>p<\/jats:italic>\u2009=\u20090.023) compared to the remaining 210 patients. Of the 34 LGLL patients with isolated anemia, 13 (38%) presented with pure red cell aplasia (PRCA), markedly decreased reticulocyte count and erythroid precursors, and more transfusion-dependence when compared to non-PRCA patients. There was no other significant clinicopathologic difference between PRCA and non-PRCA patients. 32 patients were followed for a median duration of 51 months (6\u2013199). 24 patients were treated (11\/11 PRCA and 13\/21 non-PRCA patients,<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.02). The overall response rate to first-line therapy was 83% [8\/11 (72.7%) for PRCA, 12\/13 (92.3%) for non-PRCA], including 14 showing complete response and 6 showing partial response with a median response duration of 48 months (12\u2013129). Half of non-PRCA patients who were observed experienced progressive anemia. During follow-up, no patients developed neutropenia; however, 5\/27 (18.5%) patients developed thrombocytopenia. No significant difference in overall survival was noted between PRCA and non-PRCA patients. In summary, this study demonstrates the unique features of LGLL with isolated anemia and underscores the importance of recognizing LGLL as a potential cause of isolated anemia, which may benefit from disease-specific treatment. LGLL patients with PRCA were more likely to require treatment but demonstrated similar clinicopathologic features, therapeutic responses, and overall survival compared to isolated anemia without PRCA, suggesting PRCA and non-PRCA of T-LGLL belong to a common disease spectrum.<\/jats:p>","DOI":"10.1038\/s41408-022-00632-6","type":"journal-article","created":{"date-parts":[[2022,2,22]],"date-time":"2022-02-22T15:02:56Z","timestamp":1645542176000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Isolated anemia in patients with large granular lymphocytic leukemia (LGLL)"],"prefix":"10.1038","volume":"12","author":[{"given":"Youssef","family":"Salama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1792-5822","authenticated-orcid":false,"given":"Dragan","family":"Jevremovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8284-3495","authenticated-orcid":false,"given":"Ronald S.","family":"Go","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9811-4601","authenticated-orcid":false,"given":"Wei","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3221-7314","authenticated-orcid":false,"given":"Sameer A.","family":"Parikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5359-336X","authenticated-orcid":false,"given":"Mithun V.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1292-3024","authenticated-orcid":false,"given":"Paul J.","family":"Hampel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0824-3715","authenticated-orcid":false,"given":"Aref","family":"Al-Kali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William G.","family":"Morice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5741-4293","authenticated-orcid":false,"given":"Min","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,22]]},"reference":[{"key":"632_CR1","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 2016;127:2375\u201390.","journal-title":"Blood"},{"key":"632_CR2","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1182\/blood-2016-08-692590","volume":"129","author":"T Lamy","year":"2017","unstructured":"Lamy T, Moignet A, Loughran TP. LGL leukemia: from pathogenesis to treatment. Blood. 2017;129:1082\u201394.","journal-title":"Blood"},{"key":"632_CR3","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.beha.2019.06.006","volume":"32","author":"G Barila","year":"2019","unstructured":"Barila G, Calabretto G, Teramo A, Vicenzetto C, Gasparini VR, Semenzato G, et al. T cell large granular lymphocyte leukemia and chronic NK lymphocytosis. Best Pract Res Clin Haematol 2019;32:207\u201316.","journal-title":"Best Pract Res Clin Haematol"},{"key":"632_CR4","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.3324\/haematol.2009.012161","volume":"94","author":"R Zambello","year":"2009","unstructured":"Zambello R, Semenzato G. Large granular lymphocyte disorders: new etiopathogenetic clues as a rationale for innovative therapeutic approaches. Haematologica 2009;94:1341\u20135.","journal-title":"Haematologica"},{"key":"632_CR5","doi-asserted-by":"publisher","first-page":"503","DOI":"10.3109\/10428194.2014.927459","volume":"56","author":"AD Viny","year":"2015","unstructured":"Viny AD, Maciejewski JP. High rate of both hematopoietic and solid tumors associated with large granular lymphocyte leukemia. Leuk Lymphoma. 2015;56:503\u20134.","journal-title":"Leuk Lymphoma"},{"key":"632_CR6","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/hon.917","volume":"28","author":"R Zhang","year":"2010","unstructured":"Zhang R, Shah MV, Loughran TP Jr. The root of many evils: indolent large granular lymphocyte leukaemia and associated disorders. Hematol Oncol. 2010;28:105\u201317.","journal-title":"Hematol Oncol"},{"key":"632_CR7","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1038\/s41375-019-0601-y","volume":"34","author":"J Durrani","year":"2020","unstructured":"Durrani J, Awada H, Kishtagari A, Visconte V, Kerr C, Adema V, et al. Large granular lymphocytic leukemia coexists with myeloid clones and myelodysplastic syndrome. Leukemia 2020;34:957\u201362.","journal-title":"Leukemia"},{"key":"632_CR8","doi-asserted-by":"publisher","first-page":"e169","DOI":"10.1016\/j.clml.2014.04.001","volume":"14","author":"J Cheng","year":"2014","unstructured":"Cheng J, Talamo G, Malysz J, Ochmann M, Lamy T, Loughran TP Jr. Report of 6 cases of large granular lymphocytic leukemia and plasma cell dyscrasia. Clin Lymphoma Myeloma Leuk. 2014;14:e169\u201372.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"632_CR9","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1093\/ajcp\/aqx146","volume":"149","author":"T Goyal","year":"2018","unstructured":"Goyal T, Thakral B, Wang SA, Bueso-Ramos CE, Shi M, Jevremovic D, et al. T-cell large granular lymphocytic leukemia and coexisting B-cell lymphomas: a study from the bone marrow pathology group. Am J Clin Pathol. 2018;149:164\u201371.","journal-title":"Am J Clin Pathol"},{"key":"632_CR10","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1046\/j.1365-2257.2000.00294.x","volume":"22","author":"JF Lesesve","year":"2000","unstructured":"Lesesve JF, Feugier P, Lamy T, Bene MC, Gregoire MJ, Lenormand B, et al. Association of B-chronic lymphocytic leukaemia and T-large granular lymphocyte leukaemia. Clin Lab Haematol. 2000;22:121\u20132.","journal-title":"Clin Lab Haematol"},{"key":"632_CR11","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1182\/blood.V99.1.268","volume":"99","author":"WG Morice","year":"2002","unstructured":"Morice WG, Kurtin PJ, Tefferi A, Hanson CA. Distinct bone marrow findings in T-cell granular lymphocytic leukemia revealed by paraffin section immunoperoxidase stains for CD8, TIA-1, and granzyme B. Blood 2002;99:268\u201374.","journal-title":"Blood"},{"key":"632_CR12","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1002\/cyto.b.21782","volume":"98","author":"M Shi","year":"2020","unstructured":"Shi M, Jevremovic D, Otteson GE, Timm MM, Olteanu H, Horna P. Single antibody detection of T-cell receptor alphabeta clonality by flow cytometry rapidly identifies mature T-cell neoplasms and monotypic small CD8-positive subsets of uncertain significance. Cytom B Clin Cytom. 2020;98:99\u2013107.","journal-title":"Cytom B Clin Cytom"},{"key":"632_CR13","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/ajcp\/aqaa214","volume":"156","author":"P Horna","year":"2021","unstructured":"Horna P, Olteanu H, Jevremovic D, Otteson GE, Corley H, Ding W, et al. Single-antibody evaluation of T-cell receptor beta constant chain monotypia by flow cytometry facilitates the diagnosis of T-cell large granular lymphocytic leukemia. Am J Clin Pathol. 2021;156:139\u201348.","journal-title":"Am J Clin Pathol"},{"key":"632_CR14","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1038\/leu.2009.304","volume":"24","author":"WG Morice","year":"2010","unstructured":"Morice WG, Jevremovic D, Olteanu H, Roden A, Nowakowski G, Kroft S, et al. Chronic lymphoproliferative disorder of natural killer cells: a distinct entity with subtypes correlating with normal natural killer cell subsets. Leukemia 2010;24:881\u20134.","journal-title":"Leukemia"},{"key":"632_CR15","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1182\/blood.2019001146","volume":"134","author":"S Coffy","year":"2019","unstructured":"Coffy S, Shi M. Giant intracytoplasmic inclusions in a T-cell large granular lymphocytic leukemia patient with acute severe anemia. Blood 2019;134:492.","journal-title":"Blood"},{"key":"632_CR16","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1016\/j.transproceed.2020.02.183","volume":"52","author":"G Alfano","year":"2020","unstructured":"Alfano G, Ferrari A, Fontana F, Damiano F, Solazzo A, Mori G, et al. Hemolytic anemia as presentation of T-cell large granular lymphocytic leukemia after kidney transplantation: a case report. Transplant Proc 2020;52:1617\u20138.","journal-title":"Transplant Proc"},{"key":"632_CR17","doi-asserted-by":"publisher","first-page":"31","DOI":"10.2147\/OTT.S115892","volume":"10","author":"C Bagacean","year":"2017","unstructured":"Bagacean C, Tempescul A, Patiu M, Fetica B, Bumbea H, Zdrenghea M. Atypical aleukemic presentation of large granular lymphocytic leukemia: a case report. Onco Targets Ther. 2017;10:31\u20134.","journal-title":"Onco Targets Ther"},{"key":"632_CR18","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1182\/blood.V98.2.483","volume":"98","author":"RS Go","year":"2001","unstructured":"Go RS, Li CY, Tefferi A, Phyliky RL. Acquired pure red cell aplasia associated with lymphoproliferative disease of granular T lymphocytes. Blood 2001;98:483\u20135.","journal-title":"Blood"},{"key":"632_CR19","doi-asserted-by":"publisher","first-page":"3000","DOI":"10.1182\/blood.V87.7.3000.bloodjournal8773000","volume":"87","author":"MQ Lacy","year":"1996","unstructured":"Lacy MQ, Kurtin PJ, Tefferi A. Pure red cell aplasia: association with large granular lymphocyte leukemia and the prognostic value of cytogenetic abnormalities. Blood 1996;87:3000\u20136.","journal-title":"Blood"},{"key":"632_CR20","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.3324\/haematol.12871","volume":"93","author":"N Fujishima","year":"2008","unstructured":"Fujishima N, Sawada K, Hirokawa M, Oshimi K, Sugimoto K, Matsuda A, et al. Long-term responses and outcomes following immunosuppressive therapy in large granular lymphocyte leukemia-associated pure red cell aplasia: a Nationwide Cohort Study in Japan for the PRCA Collaborative Study Group. Haematologica 2008;93:1555\u20139.","journal-title":"Haematologica"},{"key":"632_CR21","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1182\/asheducation-2016.1.51","volume":"2016","author":"RT Means Jr","year":"2016","unstructured":"Means RT Jr. Pure red cell aplasia. Hematol Am Soc Hematol Educ Program. 2016;2016:51\u20136.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"632_CR22","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1111\/j.1365-2141.2008.07216.x","volume":"142","author":"K Sawada","year":"2008","unstructured":"Sawada K, Fujishima N, Hirokawa M. Acquired pure red cell aplasia: updated review of treatment. Br J Haematol. 2008;142:505\u201314.","journal-title":"Br J Haematol"},{"key":"632_CR23","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.humpath.2017.12.014","volume":"73","author":"M Shi","year":"2018","unstructured":"Shi M, He R, Feldman AL, Viswanatha DS, Jevremovic D, Chen D, et al. STAT3 mutation and its clinical and histopathologic correlation in T-cell large granular lymphocytic leukemia. Hum Pathol. 2018;73:74\u201381.","journal-title":"Hum Pathol"},{"key":"632_CR24","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.humpath.2018.06.023","volume":"81","author":"JL Neff","year":"2018","unstructured":"Neff JL, Rangan A, Jevremovic D, Nguyen PL, Chiu A, Go RS, et al. Mixed-phenotype large granular lymphocytic leukemia: a rare subtype in the large granular lymphocytic leukemia spectrum. Hum Pathol. 2018;81:96\u2013104.","journal-title":"Hum Pathol"},{"key":"632_CR25","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1038\/leu.2012.246","volume":"26","author":"AW Langerak","year":"2012","unstructured":"Langerak AW, Groenen PJ, Br\u00fcggemann M, Beldjord K, Bellan C, Bonello L. et al. EuroClonality\/BIOMED-2 guidelines for interpretation and reporting of Ig\/TCR clonality testing in suspected lymphoproliferations. Leukemia. 2012;26:2159\u201371.","journal-title":"Leukemia"},{"key":"632_CR26","doi-asserted-by":"publisher","first-page":"3048","DOI":"10.1182\/blood-2012-06-435297","volume":"120","author":"A Jerez","year":"2012","unstructured":"Jerez A, Clemente MJ, Makishima H, Koskela H, Leblanc F, Peng NG, et al. STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia. Blood 2012;120:3048\u201357.","journal-title":"Blood"},{"key":"632_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-0275-8","volume":"10","author":"A Ravindran","year":"2020","unstructured":"Ravindran A, He R, Ketterling RP, Jawad MD, Chen D, Oliveira JL, et al. The significance of genetic mutations and their prognostic impact on patients with incidental finding of isolated del(20q) in bone marrow without morphologic evidence of a myeloid neoplasm. Blood Cancer J. 2020;10:7.","journal-title":"Blood Cancer J"},{"key":"632_CR28","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1038\/leu.2014.298","volume":"29","author":"TP Loughran Jr","year":"2015","unstructured":"Loughran TP Jr, Zickl L, Olson TL, Wang V, Zhang D, Rajala HL, et al. Immunosuppressive therapy of LGL leukemia: prospective multicenter phase II study by the Eastern Cooperative Oncology Group (E5998). Leukemia 2015;29:886\u201394.","journal-title":"Leukemia"},{"key":"632_CR29","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.3109\/10428194.2015.1081191","volume":"57","author":"M Shi","year":"2016","unstructured":"Shi M, Neff JL, Jevremovic D, Morice WG. Decreased normal NK-cells is a characteristic of T-cell large granular lymphocytic leukemia and is strongly associated with cytopenia. Leuk Lymphoma. 2016;57:1230\u20133.","journal-title":"Leuk Lymphoma"},{"key":"632_CR30","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1309\/2VQLDHVJB9YW83KB","volume":"129","author":"CA Hanson","year":"2008","unstructured":"Hanson CA, Steensma DP, Hodnefield JM, Nguyen PL, Hoyer JD, Viswanatha DS, et al. Isolated trisomy 15: a clonal chromosome abnormality in bone marrow with doubtful hematologic significance. Am J Clin Pathol. 2008;129:478\u201385.","journal-title":"Am J Clin Pathol"},{"key":"632_CR31","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1016\/j.leukres.2011.05.002","volume":"35","author":"AE Wiktor","year":"2011","unstructured":"Wiktor AE, Van Dyke DL, Hodnefield JM, Eckel-Passow J, Hanson CA. The significance of isolated Y chromosome loss in bone marrow metaphase cells from males over age 50 years. Leuk Res. 2011;35:1297\u2013300.","journal-title":"Leuk Res"},{"key":"632_CR32","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.3324\/haematol.2009.018481","volume":"95","author":"B Bareau","year":"2010","unstructured":"Bareau B, Rey J, Hamidou M, Donadieu J, Morcet J, Reman O, et al. Analysis of a French cohort of patients with large granular lymphocyte leukemia: a report on 229 cases. Haematologica 2010;95:1534\u201341.","journal-title":"Haematologica"},{"key":"632_CR33","doi-asserted-by":"publisher","first-page":"106299","DOI":"10.1016\/j.leukres.2020.106299","volume":"90","author":"Y Zhu","year":"2020","unstructured":"Zhu Y, Gao Q, Hu J, Liu X, Guan D, Zhang F. Clinical features and treatment outcomes in patients with T-cell large granular lymphocytic leukemia: a single-institution experience. Leuk Res. 2020;90:106299.","journal-title":"Leuk Res"},{"key":"632_CR34","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1111\/bjh.16808","volume":"192","author":"Z Braunstein","year":"2021","unstructured":"Braunstein Z, Mishra A, Staub A, Freud AG, Porcu P, Brammer JE. Clinical outcomes in T-cell large granular lymphocytic leukaemia: prognostic factors and treatment response. Br J Haematol. 2021;192:484\u201393.","journal-title":"Br J Haematol"},{"key":"632_CR35","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1002\/ajh.26183","volume":"96","author":"N Dong","year":"2021","unstructured":"Dong N, Castillo Tokumori F, Isenalumhe L, Zhang Y, Tandon A, Knepper TC, et al. Large granular lymphocytic leukemia - a retrospective study of 319 cases. Am J Hematol. 2021;96:772\u201380.","journal-title":"Am J Hematol"},{"key":"632_CR36","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1080\/10428194.2017.1339880","volume":"59","author":"SR Sanikommu","year":"2018","unstructured":"Sanikommu SR, Clemente MJ, Chomczynski P, Afable MG, Jerez A, Thota S, et al. Clinical features and treatment outcomes in large granular lymphocytic leukemia (LGLL). Leuk Lymphoma. 2018;59:416\u201322.","journal-title":"Leuk Lymphoma"},{"key":"632_CR37","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1093\/toxsci\/kfm098","volume":"99","author":"J Thomas","year":"2007","unstructured":"Thomas J, Haseman JK, Goodman JI, Ward JM, Loughran TP Jr, Spencer PJ. A review of large granular lymphocytic leukemia in Fischer 344 rats as an initial step toward evaluating the implication of the endpoint to human cancer risk assessment. Toxicol Sci. 2007;99:3\u201319.","journal-title":"Toxicol Sci"},{"key":"632_CR38","doi-asserted-by":"crossref","unstructured":"Rivero A, Mozas P, Jimenez L, Lopez-Guerra M, Colomer D, Bataller A, et al. Clinicobiological characteristics and outcomes of patients with T-cell large granular lymphocytic leukemia and chronic lymphoproliferative disorder of natural killer cells from a single institution. Cancers. 2021;13:3900.","DOI":"10.3390\/cancers13153900"},{"key":"632_CR39","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1111\/bjh.16336","volume":"189","author":"H Awada","year":"2020","unstructured":"Awada H, Mahfouz RZ, Durrani J, Kishtagari A, Jagadeesh D, Lichtin AE, et al. Large granular lymphocytic leukaemia after solid organ and haematopoietic stem cell transplantation. Br J Haematol. 2020;189:318\u201322.","journal-title":"Br J Haematol"},{"key":"632_CR40","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1001\/archinte.166.13.1380","volume":"166","author":"L Ferrucci","year":"2006","unstructured":"Ferrucci L, Maggio M, Bandinelli S, Basaria S, Lauretani F, Ble A, et al. Low testosterone levels and the risk of anemia in older men and women. Arch Intern Med. 2006;166:1380\u20138.","journal-title":"Arch Intern Med"},{"key":"632_CR41","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1002\/(SICI)1096-8652(199811)59:3<230::AID-AJH8>3.0.CO;2-2","volume":"59","author":"R Fonseca","year":"1998","unstructured":"Fonseca R, Rajkumar SV, White WL, Tefferi A, Hoagland HC. Anemia after orchiectomy. Am J Hematol. 1998;59:230\u20133.","journal-title":"Am J Hematol"},{"key":"632_CR42","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1182\/asheducation-2017.1.181","volume":"2017","author":"T Gazitt","year":"2017","unstructured":"Gazitt T, Loughran TP Jr. Chronic neutropenia in LGL leukemia and rheumatoid arthritis. Hematol Am Soc Hematol Educ Program. 2017;2017:181\u20136.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"632_CR43","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/S0037-1963(03)00140-9","volume":"40","author":"RS Go","year":"2003","unstructured":"Go RS, Lust JA, Phyliky RL. Aplastic anemia and pure red cell aplasia associated with large granular lymphocyte leukemia. Semin Hematol. 2003;40:196\u2013200.","journal-title":"Semin Hematol"},{"key":"632_CR44","doi-asserted-by":"publisher","first-page":"2704","DOI":"10.1182\/bloodadvances.2018022723","volume":"2","author":"T Kawakami","year":"2018","unstructured":"Kawakami T, Sekiguchi N, Kobayashi J, Imi T, Matsuda K, Yamane T, et al. Frequent STAT3 mutations in CD8(+) T cells from patients with pure red cell aplasia. Blood Adv. 2018;2:2704\u201312.","journal-title":"Blood Adv"},{"key":"632_CR45","doi-asserted-by":"publisher","first-page":"221","DOI":"10.3324\/haematol.2017.175810","volume":"103","author":"SK Balasubramanian","year":"2018","unstructured":"Balasubramanian SK, Sadaps M, Thota S, Aly M, Przychodzen BP, Hirsch CM, et al. Rational management approach to pure red cell aplasia. Haematologica 2018;103:221\u201330.","journal-title":"Haematologica"},{"key":"632_CR46","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1056\/NEJMoa1114885","volume":"366","author":"HL Koskela","year":"2012","unstructured":"Koskela HL, Eldfors S, Ellonen P, van Adrichem AJ, Kuusanmaki H, Andersson EI, et al. Somatic STAT3 mutations in large granular lymphocytic leukemia. New Engl J Med. 2012;366:1905\u201313.","journal-title":"New Engl J Med"},{"key":"632_CR47","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1111\/cas.12341","volume":"105","author":"F Ishida","year":"2014","unstructured":"Ishida F, Matsuda K, Sekiguchi N, Makishima H, Taira C, Momose K, et al. STAT3 gene mutations and their association with pure red cell aplasia in large granular lymphocyte leukemia. Cancer Sci. 2014;105:342\u20136.","journal-title":"Cancer Sci"},{"key":"632_CR48","doi-asserted-by":"publisher","first-page":"8229","DOI":"10.2147\/OTT.S222378","volume":"12","author":"ZY Qiu","year":"2019","unstructured":"Qiu ZY, Qin R, Tian GY, Wang Y, Zhang YQ. Pathophysiologic mechanisms and management of large granular lymphocytic leukemia associated pure red cell aplasia. Onco Targets Ther. 2019;12:8229\u201340.","journal-title":"Onco Targets Ther"},{"key":"632_CR49","doi-asserted-by":"publisher","first-page":"2764","DOI":"10.1182\/blood-2010-07-296962","volume":"117","author":"T Lamy","year":"2011","unstructured":"Lamy T, Loughran TP Jr. How I treat LGL leukemia. Blood 2011;117:2764\u201374.","journal-title":"Blood"},{"key":"632_CR50","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/j.1365-2141.1986.tb07495.x","volume":"63","author":"JL Abkowitz","year":"1986","unstructured":"Abkowitz JL, Kadin ME, Powell JS, Adamson JW. Pure red cell aplasia: lymphocyte inhibition of erythropoiesis. Br J Haematol 1986;63:59\u201367.","journal-title":"Br J Haematol"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-022-00632-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-022-00632-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-022-00632-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T00:53:35Z","timestamp":1726707215000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-022-00632-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,22]]},"references-count":50,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,2]]}},"alternative-id":["632"],"URL":"https:\/\/doi.org\/10.1038\/s41408-022-00632-6","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,22]]},"assertion":[{"value":"3 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.A.P.: research funding has been provided to the institution from Pharmacyclics, MorphoSys, Janssen, AstraZeneca, TG Therapeutics, Bristol Myers Squibb, Merck, AbbVie, and Ascentage Pharma for clinical studies in which S.A.P. is a principal investigator. He has received honoraria for participation in consulting activities\/advisory board meetings for Pharmacyclics, AstraZeneca, Genentech, GlaxoSmithKline, Adaptive Biotechnologies, and AbbVie (no personal compensation); and from Aptitude Health, Curio Science, and MedEd on the Go (with personal compensation). A.A.: received support to the institution from Novartis, Astex, Celgene\/BMS, Onconova, Aprea, AstraZeneca. W.D.: research funding received from Merck, AbbVie, Astrazeneca, Bristol Myers Squibb, Octapharma, DTRM pharma directed to the institution where Dr. Ding is a principal investigator. She also has participated in advisory board meetings\/steering committees for BeiGene, Octapharma, Alexion, AbbVie, and Merck without personal compensation. Other authors have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"30"}}